Serelaxin Inhibits Lipopolysaccharide-induced Inflammatory Response in Cardiac Fibroblasts by Activating Peroxisome Proliferator-activated Receptor-γ and Suppressing the Nuclear Factor-Kappa B Signaling Pathway

Xueping Wu(Chengdu Center for Disease Control and Prevention), Zhifang Yang(Shanghai University of Medicine and Health Sciences)
Journal of Cardiovascular Pharmacology
July 6, 2023
Cited by 5


Related Papers